BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 15, 2025
Home » Money raised by biotech in 2016 vs. 2015

Money raised by biotech in 2016 vs. 2015

Feb. 5, 2016

Article reprints

To read more on related topics, click on one of the words below.

BioWorld

    • Related Articles

      Money raised by biotech in 2016 vs. 2015

      Money raised by biotech in 2016 vs. 2015

      Money raised by biotech in 2016 vs. 2015

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for Dec. 15, 2025.

    • Today's news in brief

      BioWorld MedTech
      BioWorld MedTech briefs for Dec. 16, 2025.
    • Acute myeloid leukemia illustration

      Apollo’s APL-4098 shows potent antileukemic effects

      BioWorld Science
      Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
    • Novo Nordisk semaglutide pill

      CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

      BioWorld
      A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
    • CT scan of brain showing subdural hematoma

      FDA greenlights Medtronic Onyx subdural hematoma treatment

      BioWorld MedTech
      Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld MedTech
      • Today's news
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/Metabolic
      • Immune
      • Infection
      • Neurology/Psychiatric
      • NME Digest
      • Patents
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing